ILMN

Illumina Inc

Healthcare


Presented:03/03/2021
Price:$416.41
Cap:$60.75B
Current Price:$147.61
Cap:$23.51B

Presented

Date03/03/2021
Price$416.41
Market Cap$60.75B
Ent Value$52.82B
P/E Ratio93.7x
Book Value$32.15
Div Yield0%
Shares O/S145.90M
Ave Daily Vol1,115,842
Short Int2.97%

Current

Price$147.61
Market Cap$23.51B
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Publicly traded companies mentioned herein: Illumina Inc (ILMN) 

Highlights

The presenter is short shares of Illumina Inc (ILMN) and sees it as a good way to play the oversupply of tests that will come from the rise of vaccines and abatement of COVID-19 testing. He believes this has already begun and by June there will be a glut of vaccines. For these reasons he views ILMN as an extremely expensive stock at ~$425/share. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.